Eli Lilly and Company
ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES
Last updated:
Abstract:
The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation.
Status:
Application
Type:
Utility
Filling date:
15 Mar 2019
Issue date:
25 Feb 2021